Skip to main content

Peer Review reports

From: Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience

Original Submission
15 Jan 2025 Submitted Original manuscript
17 Jan 2025 Author responded Author comments - Soheila Rezaei
3 Feb 2025 Author responded Author comments - Soheila Rezaei
Resubmission - Version 2
17 Jan 2025 Submitted Manuscript version 2
27 Feb 2025 Reviewed Reviewer Report
26 Mar 2025 Reviewed Reviewer Report - Hosein Ameri
4 May 2025 Author responded Author comments - Soheila Rezaei
Resubmission - Version 3
4 May 2025 Submitted Manuscript version 3
Publishing
12 May 2025 Editorially accepted
17 May 2025 Article published 10.1186/s12913-025-12876-6

You can find further information about peer review here.

Back to article page